## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.2% below STRENGTH zone (4.0-10.0%); PEG 1.65 fails VALUE criteria (<1.0); RSI 70 overbought. Stock is in no-man's land without clear edge. Caution: declining volume (53% of avg), overbought RSI (70).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.13)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. New research highlights Hologic’s AI tools for mammography**
- Source: DOTmed | 20251201T190447 | Somewhat-Bullish | Relevance: 100%
- New clinical data presented at RSNA 2025 highlights Hologic’s AI-based mammography technologies, including 3DQuorum and Genius AI Detection solutions. A retrospective study on 3DQuorum found it maintained cancer detection rates while improving workflow efficiency. Another study on Genius AI Detection showed higher cancer detection but reduced specificity, indicating an ongoing evaluation.

**2. New research highlights Hologic’s AI tools for mammography**
- Source: DOTmed | 20251201T190442 | Bullish | Relevance: 100%
- New clinical data presented at RSNA 2025 highlights Hologic's AI-based mammography technologies, 3DQuorum and Genius AI Detection. A study on 3DQuorum showed it maintains cancer detection rates while improving workflow efficiency, potentially addressing staffing shortages. Another ongoing study on Genius AI Detection indicated higher cancer detection but also increased false positives, alongside Hologic showcasing Envision mammography and hosting educational events.

**3. Skandinaviska Enskilda Banken AB publ Sells 57,000 Shares of Hologic, Inc. $HOLX**
- Source: MarketBeat | 20251201T090808 | Neutral | Relevance: 100%
- Skandinaviska Enskilda Banken AB publ significantly reduced its holdings in Hologic, Inc. (NASDAQ:HOLX) by 26.4%, selling 57,000 shares and ending with 158,964 shares valued at $10.36 million. Despite this reduction, other major investors like Norges Bank, Allspring, Black Creek, and Invesco increased their positions, indicating strong institutional interest. Hologic reported a recent earnings beat with $1.13 EPS against an estimated $1.10 and revenue of $1.05 billion, while analysts maintain an average "Hold" rating with a $79.67 consensus price target.

**4. Why Is Hologic (HOLX) Up 1% Since Last Earnings Report?**
- Source: Nasdaq | 20251203T170958 | Somewhat-Bullish | Relevance: 100%
- Hologic (HOLX) shares have increased by 1% since its last earnings report, outperforming the S&P 500. The company surpassed Q4 earnings and revenue estimates, reporting adjusted EPS of $1.13 and revenues of $1.05 billion. Estimates for the stock have been trending upward, with Hologic currently holding a Zacks Rank #3 (Hold).

**5. Korea Investment CORP Sells 60,900 Shares of Hologic, Inc. $HOLX**
- Source: MarketBeat | 20251203T160822 | Neutral | Relevance: 100%
- Korea Investment CORP reduced its stake in Hologic, Inc. by 43.6% in the second quarter, selling 60,900 shares and retaining 78,931 shares valued at $5.14 million. This move comes as other institutional investors have either increased or initiated positions in Hologic, while company insiders, including CEO Stephen P. Macmillan and Director Christiana Stamoulis, have also sold significant shares. Hologic recently reported robust earnings, beating estimates with EPS of $1.13 and revenue of $1.05 billion, leading to a consensus "Hold" rating from analysts with an average price target of $79.67.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $76 | $69 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 15 ($0.00M) |
| Sells | 26 ($6.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Insider selling cluster: $6.6M in recent transactions.
2. Overbought RSI (70) with bearish MACD signals exhaustion.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.65 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.8x). Analyst sentiment positive (1 raises, avg +10%). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.6B |
| Beta | 0.70 |
| 52W Range | $51.90 - $75.34 |
| Short Interest | 2.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.65 |
| Forward P/E | 15.0 |
| Current P/E | 16.5 |
| YoY Growth | 9.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.0% to -1.2% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.2pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 70, risk of mean reversion. Volume at 53% of 20MA suggests lack of conviction. OFD pattern: +MUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.16% (CS: 40) | Neutral |
| RSI_14 | 70.3 | Overbought |
| MACD Histogram | -0.14 | Bearish |
| vs SMA20 | 1.007x | Above |
| vs SMA50 | 1.045x | Above |
| vs SMA200 | 1.151x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $75.01
- **Stop Loss:** $74.13 (1.2% risk)
- **Target:** $75.89 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1079
- **Position Value:** $80,935.79
- **Portfolio %:** 80.94%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*